{"filing":{"accession_number":"0001213900-26-074946","cik":"0001893645","ticker":"PLRZ","company_name":"Polyrizon Ltd.","form":"6-K","filing_date":"2026-07-02","report_date":null,"primary_document":"ea0296863-6k_polyrizon.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1893645/000121390026074946/ea0296863-6k_polyrizon.htm"},"events":[{"id":15796,"run_id":14090,"accession_number":"0001213900-26-074946","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces successful completion of biocompatibility testing for NASARIX, a development-stage medical device product. The disclosure describes achievement of a pre-clinical regulatory milestone—passing all required biological safety assessments under ISO 10993 standards—that supports advancement toward first-in-human clinical trials. While this is a material operational/development milestone for a biotech company, it does not fit the specific event categories (earnings, M\u0026A, executive changes, impairment, etc.); it is a product development achievement that materially advances the company's clinical and regulatory pathway.","company_name":"Polyrizon Ltd.","ticker":"PLRZ","filing_date":"2026-07-02","form":"6-K","submitted_at":null,"items":[{"id":13692,"accession_number":"0001213900-26-074946","item_number":"EX-99.1","item_title":"ea029686301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces successful completion of biocompatibility testing for NASARIX, a development-stage medical device product. The disclosure describes achievement of a pre-clinical regulatory milestone—passing all required biological safety assessments under ISO 10993 standards—that supports advancement toward first-in-human clinical trials. While this is a material operational/development milestone for a biotech company, it does not fit the specific event categories (earnings, M\u0026A, executive changes, impairment, etc.); it is a product development achievement that materially advances the company's clinical and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:01:55.532036+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13692,"accession_number":"0001213900-26-074946","item_number":"EX-99.1","item_title":"ea029686301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces successful completion of biocompatibility testing for NASARIX, a development-stage medical device product. The disclosure describes achievement of a pre-clinical regulatory milestone—passing all required biological safety assessments under ISO 10993 standards—that supports advancement toward first-in-human clinical trials. While this is a material operational/development milestone for a biotech company, it does not fit the specific event categories (earnings, M\u0026A, executive changes, impairment, etc.); it is a product development achievement that materially advances the company's clinical and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:01:55.532036+00:00","company_name":"Polyrizon Ltd.","ticker":"PLRZ","filing_date":"2026-07-02"}]}